# UK MHRA extends Casgevy gene-editing approval to children aged five and over

> The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.

- Canonical URL: https://newsverum.com/en/news/uk-mhra-casgevy-gene-editing-children-approval-2026
- Publisher: Newsverum
- Section: Health
- Country: United Kingdom
- Published: 2026-10-31T22:01:30+00:00
- Updated: 2026-11-01T00:43:00Z
- Event / data period: 2026-10-29
- Other editions: [Türkçe](https://newsverum.com/tr/news/uk-mhra-casgevy-gene-editing-children-approval-2026.md), [العربية](https://newsverum.com/ar/news/uk-mhra-casgevy-gene-editing-children-approval-2026.md), [Français](https://newsverum.com/fr/news/uk-mhra-casgevy-gene-editing-children-approval-2026.md), [Español](https://newsverum.com/es/news/uk-mhra-casgevy-gene-editing-children-approval-2026.md), [Deutsch](https://newsverum.com/de/news/uk-mhra-casgevy-gene-editing-children-approval-2026.md), [Português](https://newsverum.com/pt/news/uk-mhra-casgevy-gene-editing-children-approval-2026.md)

Casgevy (exagamglogene autotemcel) was previously restricted to patients aged 12 and above. The therapy edits the patient’s harvested haematopoietic stem cells in a laboratory to reactivate fetal haemoglobin production, before reinfusing them following myeloablative conditioning.

The regulator confirmed that the expansion follows evaluation of clinical trials demonstrating significant reductions in vaso-occlusive pain crises and transfusion dependency in younger age cohorts. Treatment requires specialized cell-therapy centres and rigorous post-infusion monitoring for complications such as cytopenias and infections.

## Data

### Source publication

Publication of the official approval extension announcement on 29 October 2026.

Methodology: The date records publication of the cited primary source. Regulatory scope and age indications are stated in the article.

| date | label | description | status |
|---|---|---|---|
| 2026-10-29 | MHRA expands Casgevy age authorisation to children aged 5 and over | Regulatory extension granted on 29 October 2026 for pediatric sickle-cell and beta-thalassaemia patients. | occurred |

Sources: <https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders> · Download data: [JSON](https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026/data/source-announcement?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/uk-mhra-casgevy-gene-editing-children-approval-2026/data/source-announcement?lang=en&format=csv)

## Sources

- [Medicines and Healthcare products Regulatory Agency, United Kingdom](<https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders>) (Source checked: 2026-11-01; Published: 2026-10-29)

---

Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)
